Author/Authors :
Kou، نويسنده , , Geng and Shi، نويسنده , , Jingping and Chen، نويسنده , , Lin and Zhang، نويسنده , , Dapeng and Hou، نويسنده , , Sheng and Zhao، نويسنده , , Lei and Fang، نويسنده , , Chen and Zheng، نويسنده , , Lei and Zhang، نويسنده , , Xunming and Liang، نويسنده , , Ping and Zhang، نويسنده , , Xu and Li، نويسنده , , Bohua and Guo، نويسنده , , Yajun، نويسنده ,
Abstract :
Both vascular endothelial growth factor A (VEGF) and osteopontin (OPN) can directly induce tumor angiogenesis, which is essential for the growth and metastasis of solid tumors. Here we engineered a bispecific antibody (VEGF/OPN-BsAb) using the anti-VEGF-A antibody bevacizumab and the anti-OPN antibody hu1A12. Compared with hu1A12 alone and bevacizumab alone, VEGF/OPN-BsAb was significantly more effective in inhibiting tumor angiogenesis in a highly metastatic human hepatocellular carcinoma nude mouse model. Further study demonstrated that VEGF/OPN-BsAb could effectively suppress primary tumor growth and metastasis to lungs, suggesting that it might be a promising therapeutic agent for treatment of metastatic cancer.
Keywords :
Vascular endothelial growth factor , Tumor , Osteopontin , Angiogenesis , metastasis
